Sanofi Wins FDA Approval for First Neurological GD3 Treatment

Share on Social Media

Sanofi's Infilbray (venglustat) receives FDA approval as the first treatment for neurological manifestations of Type 3 Gaucher disease.
Image: Pixel

Sanofi’s Infilbray (venglustat) receives FDA approval as the first treatment for neurological manifestations of Type 3 Gaucher disease, based on Phase 3 LEAP2MONO results.

Written By: Siddhi Bhadekar, M. Pharm (QA)

Reviewed By: Pharmacally Editorial Team

The US Food and Drug Administration (FDA) approved Infilbray (venglustat) on November 18, 2026 seven days ahead of its November 25 Prescription Drug User Fee Act (PDUFA) target date as the first treatment for neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg. Sanofi’s once-daily oral glucosylceramide synthase inhibitor (GCSi) crosses the blood-brain barrier. The approval was granted to Genzyme Corporation, a Sanofi company.

FDA-Approved Indication and Regulatory Status

The indication covers neurological manifestations of GD3 in adults and children weighing at least 15 kg. The FDA identifies Orphan Drug designation and Priority Review. Sanofi also reports earlier US Breakthrough Therapy, Rare Pediatric Disease, and Fast Track designations, as well as Orphan Drug designation for GD3 in the US, EU, and Japan.

Clinical Evidence: LEAP2MONO Phase 3 Trial

The approval is based on LEAP2MONO (NCT05222906), a randomized, double-blind, double-dummy, active-comparator Phase 3 study involving 43 patients aged 12 years and older with neurological GD3. Participants had received enzyme replacement therapy (ERT) for at least three years and achieved therapeutic goals for systemic disease. They were randomized 1:1 to once-daily oral venglustat with a placebo infusion (n=21) or intravenous imiglucerase every two weeks with a placebo tablet (n=22). Treatment lasted 52 weeks.

The primary endpoint was a prespecified global test using O’Brien ordinary least squares analysis. It combined change from baseline to Week 52 in the 4-item modified Scale for the Assessment and Rating of Ataxia (mSARA), assessing motor function, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index, assessing cognition. Sanofi’s November approval announcement reported statistical superiority over imiglucerase on this combined measure (p=0.0137).

In a February 2026 topline update with full results later presented at the European Hematology Association (EHA) 2026 Congress in June Sanofi reported that the study met three of four key secondary endpoints (spleen volume, liver volume, platelet count, and hemoglobin), showing that venglustat performed similarly to ERT on systemic disease measures. The November approval announcements themselves did not reiterate endpoint-level data.

Safety Profile and Labeled Warnings

Infilbray carries Warnings and Precautions for suicidal ideation and behavior, lens opacification in pediatric patients, and embryofetal toxicity. The FDA identifies gastrointestinal and mood-related effects among the most common side effects. During the primary analysis period, adverse reactions occurring more frequently with venglustat (n=21) versus imiglucerase (n=22) included diarrhea (14% vs. 0%), splenomegaly (14% vs. 0%), nausea (14% vs. 5%), depression (10% vs. 0%), gastroenteritis (10% vs. 0%), and vomiting (10% vs. 5%). Headache was also among the most common events overall, though it occurred at a lower rate in the venglustat group than in the imiglucerase group (14% vs. 18%).

Sanofi’s patient safety information advises mental-health risk assessment before treatment and ongoing monitoring for mood or behavioral changes. Children receiving long-term treatment should have an ophthalmological examination before starting therapy and annually during treatment. Embryofetal toxicity was identified in animal studies.

Mechanism of Action and Disease Context

Venglustat inhibits glucosylceramide synthase, an enzyme involved in glycosphingolipid (GSL) production, reducing abnormal GSL accumulation in both peripheral tissues and the central nervous system (CNS). Its ability to cross the blood-brain barrier distinguishes it from conventional intravenous ERT, which addresses non-neurological manifestations but has not adequately treated CNS disease.

Gaucher disease is an inherited lysosomal storage disorder caused by deficient glucocerebrosidase activity, leading to GSL accumulation, particularly in macrophages of the spleen, liver, bone marrow, and lungs. GD1 generally lacks primary CNS involvement, GD2 is the acute neuronopathic form, and GD3 is the chronic neuronopathic form. CNS involvement in GD3 can cause cognitive impairment and ataxia alongside hepatosplenomegaly, anemia, thrombocytopenia, and bone disease.

Regulatory Outlook and Clinical Interpretation

Sanofi says Infilbray is under regulatory review for GD3 in the EU, Japan, and other jurisdictions, with further global submissions planned in 2026 and 2027. The open-label extension of LEAP2MONO is ongoing, with longer-term results expected as they mature.

LEAP2MONO provides controlled evidence of improvement on a combined neurological measure in a disease area where conventional ERT has not adequately addressed CNS manifestations. However, the study was small, with 43 participants, and the reported p-value relates to the pooled primary endpoint. The November announcements do not establish whether mSARA and RBANS each improved significantly on their own or provide enough detail to judge the magnitude and durability of clinical benefit. The long-term effect of switching from ERT on systemic disease control particularly given the observed cases of splenomegaly—also requires continued assessment.

Additionally, the approved weight-based population differs from the trial’s age criterion: the indication includes children weighing at least 15 kg, whereas LEAP2MONO enrolled patients aged 12 years and older. While FDA pediatric approvals below a pivotal trial’s minimum age typically rely on pharmacokinetic/pharmacodynamic (PK/PD) modeling and exposure-matching, the cited announcements do not detail the supporting pediatric evidence. Long-term follow-up will remain essential for assessing durability, systemic control, and safety in younger patients.

References

Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease, Sanofi, November 18, 2026

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease. US FDA, November 18, 2026.

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (LEAP2MONO), ClinicalTrials.gov ID NCT05222906

About the Writer

Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.


Share on Social Media
Scroll to Top